900522-79-4Relevant academic research and scientific papers
Binaphthyl-based dicationic peptoids with therapeutic potential
Bremner, John B.,Keller, Paul A.,Pyne, Stephen G.,Boyle, Timothy R.,Brkic, Zinka,David, Dorothy M.,Garas, Adel,Morgan, Jody,Robertson, Mark,Somphol, Kittiya,Miller, Michael H.,Howe, Adam S.,Ambrose, Paul,Bhavnani, Sujata,Fritsche, Thomas R.,Biedenbach, Douglas J.,Jones, Ronald N.,Buckheit Jr., Robert W.,Watson, Karen M.,Baylis, Dean,Coates, Jonathan A.,Deadman, John,Jeevarajah, Dharshini,McCracken, Andrea,Rhodes, David I.
supporting information; experimental part, p. 537 - 540 (2010/04/24)
(Figure Presented) Superbugs stalled! Two newly designed synthetic dicationic peptoids (see one example; red O, blue N, green Cl) show promising in vitro bactericidal activity against a range of Gram-positive pathogens, including organisms resistant to vancomycin, methicillin, and linezolid, with only slow development of resistance. Moreover their potency is maintained in vivo.
PEPTIDIC COMPOUNDS
-
Page/Page column 75, (2008/06/13)
The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.
